FVR Suomen rokotetutkimus Oy
- Address
- Mannilantie 44, 04400 Jarvenpaa, Finland
Bacterial Infections and Mycoses
The clinic is advancing protection against pneumococcal infections by testing a new conjugate vaccine in healthy toddlers, focusing on safety and immune response.
- Pneumococcal conjugate vaccine development
- Safety assessment in young children
- Immunogenicity evaluation
FVR Suomen rokotetutkimus Oy leverages its expertise to reduce bacterial disease burden through innovative pediatric studies.
Respiratory Tract Diseases
Research at the Järvenpään Rokotetutkimusklinikka targets the prevention of respiratory syncytial virus (RSV) lower respiratory illness in infants, measuring vaccine efficacy and tolerability.
- RSV vaccine efficacy trials
- Safety monitoring in infants
- Reduction of medically attended lower respiratory infections
The site’s work aims to lower RSV‑related hospitalizations and improve child health across Finland.
Virus Diseases
The center conducts broader investigations into virus diseases, including RSV and other respiratory viruses, to evaluate novel vaccine candidates and their protective benefits.
- Evaluation of new viral vaccines
- Assessment of viral infection prevention
- Monitoring of adverse events in pediatric cohorts
By focusing on viral pathogens, the site contributes to stronger community immunity and pandemic preparedness.
Immune System Processes
Studies explore fundamental immune system processes triggered by vaccination, aiming to understand how infants generate protective immunity and how tolerability is maintained.
- Immunogenicity profiling
- Safety and tolerability analysis
- Biomarker identification for vaccine response
Insights gained support the design of safer, more effective vaccines for young populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in FVR Suomen rokotetutkimus Oy
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 534 | 1 | Unknown | 2024-08-09 | 2024-08-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.